Cumulative Irritation and Sensitization
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Noven PharmaceuticalsFL - Miami
2 programs2
HP-1050 PatchPhase 11 trial
dATSPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Noven PharmaceuticalsHP-1050 Patch
Noven PharmaceuticalsdATS
Clinical Trials (2)
Total enrollment: 469 patients across 2 trials
Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch
Start: Nov 2020Est. completion: Jan 2022240 patients
Phase 1Unknown
Irritation and Sensitization Study of d-Amphetamine Transdermal System
Start: Dec 2019Est. completion: May 2020229 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.